to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Receptor Protein-Tyrosine Kinases
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Cabozantinib for the treatment of advanced medullary thyroid cancer.
New approaches to thyroid cancer.
Novel molecular targeted therapies for refractory thyroid cancer.
Forthcoming receptor tyrosine kinase inhibitors.
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
Protein Tyrosine Kinases